129 related articles for article (PubMed ID: 34695644)
1. Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.
Kannan KK; Vellanki P; Isom S; Tawfik B; Winter A; Klepin HD; Ellis LR; Bhave RR; Howard D; Manuel M; Dralle S; Lyerly S; Powell BL; Pardee TS
Leuk Res; 2021 Dec; 111():106731. PubMed ID: 34695644
[No Abstract] [Full Text] [Related]
2. Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.
Chen X; Newell LF; Xie H; Walter RB; Pagel JM; Sandhu VK; Becker PS; Hendrie PC; Abkowitz JL; Appelbaum FR; Estey EH
Leukemia; 2015 Aug; 29(8):1779-80. PubMed ID: 25650090
[No Abstract] [Full Text] [Related]
3. A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
Song J; Shang B; Pei Y; Shi M; Niu X; Dou L; Drokow EK; Xu F; Bai Y; Sun K
Leuk Res; 2021 Oct; 109():106638. PubMed ID: 34116372
[TBL] [Abstract][Full Text] [Related]
4. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.
Covut F; Gupta D; Pinto R; Dambrosio N; El Jurdi N; Meyerson H; Ueda M; Kolk M; Creger R; Metheny L; Cooper BW; Caimi PF; Malek E; Otegbeye F; Lazarus HM; De Lima M; Tomlinson BK
Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):73-82. PubMed ID: 30528848
[TBL] [Abstract][Full Text] [Related]
6. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
7. Blast crisis.
Blood; 2009 Dec; 114(24):4917. PubMed ID: 20050125
[No Abstract] [Full Text] [Related]
8. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
Dombret H; Seymour JF; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Bernal del Castillo T; Al-Ali HK; Martinelli G; Falantes J; Noppeney R; Stone RM; Minden MD; McIntyre H; Songer S; Lucy LM; Beach CL; Döhner H
Blood; 2015 Jul; 126(3):291-9. PubMed ID: 25987659
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
Short NJ; Benton CB; Chen HC; Qiu P; Gu L; Pierce S; Brandt M; Maiti A; Min TL; Naqvi K; Quintas-Cardama A; Konopleva M; Kadia T; Cortes J; Garcia-Manero G; Ravandi F; Jabbour E; Kantarjian H; Andreeff M
Am J Hematol; 2016 Dec; 91(12):1221-1226. PubMed ID: 27474808
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Linkesch W; Thaler J; Gattringer C; Konwalinka G
Haematol Blood Transfus; 1990; 33():330-2. PubMed ID: 2323638
[No Abstract] [Full Text] [Related]
11. A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia.
Refaei M; Radhwi O; Sandhu I; Brandwein J; Sun HWL; Saini L
Leuk Lymphoma; 2019 Jul; 60(7):1749-1757. PubMed ID: 31043109
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of the peripheral blood cell counts changes during induction chemotherapy in Chinese patients with adult acute myeloid leukemia.
Huang YM; Wang YN; Zheng Y; Pan LL; Li Y; Li JG; Wang SY
Medicine (Baltimore); 2021 Feb; 100(8):e24614. PubMed ID: 33663070
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine and Cytarabine Combination in the Induction of Adult Patients with Acute Myeloid Leukaemia.
Longu F; Fozza C; Dessì L; Longinotti M; Bonfigli S; Careddu MG; Coppola L; Giannico DB; Nieddu RM; Podda L; Pardini S; Dore F; Dore S; Sotgiu G
Acta Haematol; 2017; 137(1):15-16. PubMed ID: 27806360
[No Abstract] [Full Text] [Related]
14. Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts.
Griffiths EA; Golding MC; Srivastava P; Povinelli BJ; James SR; Ford LA; Wetzler M; Wang ES; Nemeth MJ
Haematologica; 2015 Feb; 100(2):e49-52. PubMed ID: 25381132
[No Abstract] [Full Text] [Related]
15. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
[TBL] [Abstract][Full Text] [Related]
17. Urinary excretion of proteolyzed alpha1-antitrypsin: specificity, quantitation, and relation to therapy response in patients with acute myeloid leukemia.
Dengler R; Plewan A; Münstermann U; Busch R; Eger G; Emmerich B
Clin Cancer Res; 1995 Feb; 1(2):199-205. PubMed ID: 9815974
[TBL] [Abstract][Full Text] [Related]
18. Early clearance of peripheral blasts measured by flow cytometry during the first week of AML induction therapy as a new independent prognostic factor: a GOELAMS study.
Lacombe F; Arnoulet C; Maynadié M; Lippert E; Luquet I; Pigneux A; Vey N; Casasnovas O; Witz F; Béné MC
Leukemia; 2009 Feb; 23(2):350-7. PubMed ID: 18987664
[TBL] [Abstract][Full Text] [Related]
19. Azacitidine in AML: a treatment option?
Huls G
Blood; 2015 Jul; 126(3):283-4. PubMed ID: 26185114
[TBL] [Abstract][Full Text] [Related]
20. Failure of mithramycin to control the myeloid blast phase of chronic granulocytic leukemia: a report on nine patients and review of the literature.
Johnson PR; Yin JA; Narayanan MN; Geary CG; Love EM; Cinkotai KI
Hematol Oncol; 1991; 9(1):9-15. PubMed ID: 1828453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
